Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB

Oncogene volume 23, pages 6743–6759 (2004)Cite this article

Abstract

The Hodgkin cell line HD-MyZ is resistant to apoptosis induced by tumor necrosis factor α (TNFα). In the present work, we show that pretreatment with TNFα sensitized the cells to apoptosis induced by antineoplastic agents and ceramide. TNFα pretreatment resulted in enhanced cleavage and activity of caspase-3 upon addition of etoposide, epirubicin or ceramide. No caspase-8 activation was detectable, although caspase-8 could be activated in cell-free extracts. Inhibition of caspase-8 by z-IETD-fmk did not block the sensitizing effect of TNFα. Furthermore, exogenous ceramide, a mediator of TNFα signaling, could not substitute for TNFα in sensitization to drug-induced apoptosis. In contrast, we observed mitochondrial changes following cotreatment of cells with TNFα and drugs. Mitochondrial permeability transition, cytochrome c release and subsequent processing of caspase-9 preceded the onset of apoptosis, and were enhanced by TNFα pretreatment. Interestingly, although transcription factor NF-κB protected HD-MyZ cells from drug-induced apoptosis, TNFα-mediated sensitization was independent of NF-κB, since overexpressing a dominant-negative IκB mutant did not alter the TNFα effect. Sensitization for drug-induced apoptosis by TNFα was abrogated by Bcl-xL. Thus, the sensitizing effect of TNFα is mediated by the mitochondrial pathway and involves processing of caspase-2, -3 and -9, but appears to be independent of caspase-8 processing, Bid cleavage and NF-κB signaling. Therefore, sensitization by TNFα is mediated at least in part through different pathways, as reported for TRAIL. There, sensitization occurs through a FADD/caspase-8-dependent mechanism. Regarding TNFα, the sensitizing effect was also observed in myeloid leukemia cells. Therefore, TNFα or alternate molecules activating its pathways might be useful as sensitizers for chemotherapy in hematological malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 3
Figure 10
Figure 2
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 12
Figure 11
Figure 13
Figure 14

Similar content being viewed by others

References

  • Baker SJ and Reddy EP . (1998). Oncogene, 17, 3261–3270.

  • Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dörken B . (1997). J. Clin. Invest., 12, 2961–2969.

  • Bargou RC, Mapara MY, Zugck C, Daniel PT, Pawlita M, Dohner H and Dörken B . (1993). J. Exp. Med., 177, 1257–1268.

  • Beg AA and Baltimore D . (1996). Science, 274, 782–784.

  • Belka C, Heinrich V, Marini P, Faltin H, Schulze-Osthoff K, Bamberg M and Budach W . (1999). Int. J. Radiat. Biol., 75, 1257–1264.

  • Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A, Faltin H, Bamberg M, Budach W and Schulze-Osthoff K . (2000). Oncogene, 19, 1181–1190.

  • Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K and Budach W . (2001). Oncogene, 20, 2190–2196.

  • Beyaert R, Heyninck K and Van Huffel S . (2000). Biochem. Pharmacol., 60, 1143–1151.

  • Beyaert R, Vanhaesebroeck B, Heyninck K, Boone E, De Valck D, Schulze-Osthoff K, Haegeman G, Van Roy F and Fiers W . (1993). Cancer Res., 53, 2623–2630.

  • Blagosklonny MV . (2000). Leukemia, 14, 1502–1508.

  • Bligh EG and Dyer WJ . (1959). Can. J. Biochem. Physiol., 37, 911–917.

  • Boldin MP, Goncharov TM, Goltsev YV and Wallach D . (1996). Cell, 85, 803–815.

  • Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH and Wallach D . (1995). J. Biol. Chem., 270, 7795–7798.

  • Busuttil V, Bottero V, Frelin C, Imbert V, Ricci JE, Auberger P and Peyron JF . (2002). Oncogene, 21, 3213–3224.

  • Carpentier I and Beyaert R . (1999). FEBS Lett., 460, 246–250.

  • Carpentier I, Declercq W, Malinin NL, Wallach D, Fiers W and Beyaert R . (1998). FEBS Lett., 425, 195–198.

  • Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME and Dixit VM . (1996). J. Biol. Chem., 271, 4961–4965.

  • Cosset FL, Takeuchi Y, Battini JL, Weiss RA and Collins MK . (1995). J. Virol., 69, 7430–7436.

  • Daniel PT and Krammer PH . (1994). J. Immunol., 152, 5624–5632.

  • Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R and Dörken B . (1997). Eur. J. Immunol., 27, 1029–1034.

  • Daniel PT, Schulze-Osthoff K, Belka C and Güner D . (2003). Essays Biochem., 39, 73–88.

  • Daniel PT, Sturm I, Wieder T and Schulze-Osthoff K . (2001). Leukemia, 15, 1022–1032.

  • de Almodovar CR, Ruiz-Ruiz C, Munoz-Pinedo C, Robledo G and Lopez-Rivas A . (2001). Oncogene, 20, 7128–7133.

  • Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou J . (1999). J. Cell. Biol., 144, 891–901.

  • De Valck D, Jin DY, Heyninck K, Van de Craen M, Contreras R, Fiers W, Jeang KT and Beyaert R . (1999). Oncogene, 18, 4182–4190.

  • Dhein J, Behrmann I, Daniel PT, Debatin KM, Klas C, Moller P, Oehm A, Trauth BC, Walczak H and Krammer PH . (1994). Biochem. Soc. Trans., 22, 598–600.

  • Droin N, Bichat F, Rebe C, Wotawa A, Sordet O, Hammann A, Bertrand R and Solary E . (2001). Blood, 97, 1835–1844.

  • El-Deiry WS . (2001). Cell Death Differ., 8, 1066–1075.

  • Eskes R, Desagher S, Antonsson B and Martinou JC . (2000). Mol. Cell. Biol., 20, 929–935.

  • Essmann F, Wieder T, Otto A, Muller EC, Dörken B and Daniel PT . (2000). Biochem. J., 346, 777–783.

  • Fiers W, Beyaert R, Boone E, Cornelis S, Declercq W, Decoster E, Denecker G, Depuydt B, De Valck D, De Wilde G, Goossens V, Grooten J, Haegeman G, Heyninck K, Penning L, Plaisance S, Vancompernolle K, Van Criekinge W, Vandenabeele P, Vanden Berghe W, Van de Craen M, Vandevoorde V and Vercammen D . (1995). J. Inflamm., 47, 67–75.

  • Fortis C, Biswas P, Soldini L, Veglia F, Careddu AM, Delfanti F, Mantelli B, Murone M, Lazzarin A and Poli G . (1999). Eur. J. Immunol., 29, 2662–3654.

  • Friedrich K, Wieder T, von Haefen C, Radetzki S, Schulze-Osthoff K, Jänicke R, Dörken B and Daniel PT . (2001). Oncogene, 20, 2460–2749.

  • Fulda S, Meyer E and Debatin KM . (2002). Oncogene, 21, 2283–2294.

  • Geilen CC, Bektas M, Wieder T and Orfanos CE . (1996). FEBS Lett., 378, 88–92.

  • Goossens V, Grooten J, De Vos K and Fiers W . (1995). Proc. Natl. Acad. Sci. USA, 92, 8115–8119.

  • Gottlieb E, Vander Heiden MG and Thompson CB . (2000). Mol. Cell. Biol., 20, 5680–5689.

  • Gridley DS, Archambeau JO, Andres MA, Mao XW, Wright K and Slater JM . (1997). Oncol. Res., 9, 217–227.

  • Guiet C, Silvestri E, De Smaele E, Franzoso G and Vito P . (2002). Cell Death Differ., 9, 138–144.

  • Hannun YA . (1996). Science, 274, 1855–1859.

  • Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, Dörken B and Daniel PT . (2004). Oncogene, 23, 4523–4535.

  • Hemmati PG, Gillissen B, von Haefen C, Wendt J, Stärck L, Güner D, Dörken B and Daniel PT . (2002). Oncogene, 21, 3149–3161.

  • He Q, Huang Y, Sheikh MS, Troy CM and Shelanski ML . (2004). Oncogene, 23, 1321–1325.

  • Heyninck K and Beyaert R . (2001). Mol. Cell. Biol. Res. Commun., 4, 259–265.

  • Jänicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K and Porter AG . (2001). Oncogene, 20, 5043–5053.

  • Khwaja A and Taton L . (1999). J. Biol. Chem., 51, 36817–36823.

  • Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ and Lee MS . (2002). Oncogene, 21, 3139–3148.

  • Kimura K, Bowen C, Spiegel S and Gelmann EP . (1999). Cancer Res., 59, 1606–1614.

  • Kolesnick RN, Haimovitz-Friedman A and Fuks Z . (1994). Biochem. Cell. Biol., 72, 471–474.

  • Kontny HU, Hammerle K, Klein R, Shayan P, Mackall CL and Niemeyer CM . (2001). Cell Death Differ., 8, 506–514.

  • Krönke M . (1999). Chem. Phys. Lipids, 102, 157–166.

  • Lassus P, Opitz-Araya X and Lazebnik Y . (2002). Science, 297, 1352–1354.

  • Li H, Zhu H, Xu C and Yuan J . (1998). Cell, 94, 491–501.

  • Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X . (1997). Cell, 91, 479–489.

  • Los M, Wesselborg S and Schulze-Osthoff K . (1999). Immunity, 10, 629–639.

  • Luo X, Budihardjo I, Zou H, Slaughter C and Wang X . (1998). Cell, 94, 481–490.

  • Luschen S, Ussat S, Scherer G, Kabelitz D and Adam-Klages S . (2000). J. Biol. Chem., 275, 24670–24678.

  • MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH and Cohen GM . (2002). Oncogene, 21, 6809–6818.

  • Milner AE, Palmer DH, Hodgkin EA, Eliopoulos AG, Knox PG, Poole CJ, Kerr DJ and Young LS . (2002). Cell Death Differ., 9, 287–300.

  • Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME and Dixit VM . (1996). Cell, 85, 817–827.

  • Muzio M, Salvesen GS and Dixit VM . (1997). J. Biol. Chem., 272, 2952–2956.

  • O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, Kuida K, Strasser A, Huang DC and Kumar S . (2002). Cell Death Differ., 9, 832–841.

  • Paroni G, Henderson C, Schneider C and Brancolini C . (2001). J. Biol. Chem., 276, 21907–21915.

  • Perez D and White E . (2000). Mol. Cell, 6, 53–63.

  • Peter ME . (2000). Cell Death Differ., 7, 759–760.

  • Prajapati S and Gaynor RB . (2002). J. Biol. Chem., 277, 24331–24339.

  • Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B and Daniel PT . (2002). Oncogene, 21, 227–238.

  • Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z and Rothe M . (1997). Cell, 90, 373–383.

  • Robertson JD, Enoksson M, Suomela M, Zhivotovsky B and Orrenius S . (2002). J. Biol. Chem., 277, 29803–29809.

  • Roy N, Deveraux QL, Takashashi R, Salvesen GS and Reed JC . (1997). EMBO J., 16, 6914–6925.

  • Ruffolo SC, Breckenridge DG, Nguyen M, Goping IS, Gross A, Korsmeyer SJ, Li H, Yuan J and Shore GC . (2000). Cell Death Differ., 7, 1101–1108.

  • Salvesen GS and Dixit VM . (1999). Proc. Natl. Acad. Sci. USA, 96, 10964–10967.

  • Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA and Fiers W . (1992). J. Biol. Chem., 267, 5317–5323.

  • Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G and Fiers W . (1993). EMBO J., 12, 3095–3104.

  • Schwandtner R, Wiegmann K, Bernardo K, Kreder D and Krönke M . (1998). J. Biol. Chem., 273, 5916–5922.

  • Shatrov VA, Ameyar M, Bouquet C, Cai Z, Stancou R, Haddada H and Chouaib S . (2000). Int. J. Cancer, 85, 93–97.

  • Shearwin-Whyatt LM, Harvey NL and Kumar S . (2000). Cell Death Differ., 7, 155–165.

  • Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ . (1999). J. Cell. Biol., 144, 281–292.

  • Smirnov AS, Ruzov AS, Budanov AV, Prokhortchouk AV, Ivanov AV and Prokhortchouk EB . (2001). Cell Death Differ., 8, 621–630.

  • Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA and Walczak H . (2002). EMBO J., 21, 4520–4530.

  • Suffys P, Beyaert R, Van Roy F and Fiers W . (1989). Anticancer Res., 9, 167–171.

  • Troy CM and Shelanski ML . (2003). Cell Death Differ., 10, 101–107.

  • Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM . (1996). Science, 274, 787–789.

  • von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT . (2003). Oncogene, 22, 2236–2247.

  • von Haefen C, Wieder T, Gillissen B, Starck L, Graupner V, Dörken B and Daniel PT . (2002). Oncogene, 21, 4009–4019.

  • Wallach D, Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, Goncharov TM, Kovalenko AV, Rajput A, Varfolomeev EE and Zhang S . (2002). Arthritis Res., 4 (Suppl 3), S189–S196.

  • Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV and Boldin MP . (1999). Annu. Rev. Immunol., 17, 331–367.

  • Wang C, Mayo M, Korneluk R, Goeddel D and Baldwin A . (1998). Science, 281, 1680–1683.

  • Wesselborg S, Engels IH, Rossmann E, Los M and Schulze-Osthoff K . (1999). Blood, 93, 3053–3063.

  • Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B and Daniel PT . (2001a). Blood, 97, 1378–1387.

  • Wieder T, Orfanos CE and Geilen CC . (1998). J. Biol. Chem., 273, 11025–11031.

  • Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dörken B, Schmalz HG, Daniel PT and Henze G . (2001b). Leukemia, 15, 1735–1742.

  • Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J and Escandon E . (2002). Oncogene, 21, 3611–3619.

  • Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F and Ben-Neriah Y . (1998). Nature, 396, 590–594.

Download references

Acknowledgements

We thank Verena Lehmann and Clarissa von Haefen for excellent technical assistance, Florian Emmerich for providing HD-MyZ transfectants, Thilo Makros and Martin Lipp, Max-Delbrück-Center, Berlin, Germany) for the K562 cells and other members of the laboratory for helpful discussions. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Da238/4-1 and 4-2), the Deutsche Krebshilfe and the Deutsche José Carreras Leukämie-Stiftung.

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology, and Tumor Immunology, University Medical Center Charité-Campus CBB, Humboldt University, Berlin, Germany

    Karin Schmelz, Thomas Wieder, Ingo Tamm, Antje Müller, Frank Essmann, Bernd Dörken & Peter-T Daniel

  2. Department of Dermatology, University Medical Center, Charité-Campus CBF Free University, Berlin, Germany

    Christoph-C Geilen

  3. Institute for Molecular Medicine, Heinrich-Heine University, Düsseldorf, Germany

    Klaus Schulze-Osthoff

Authors
  1. Karin Schmelz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Wieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ingo Tamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antje Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frank Essmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christoph-C Geilen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Klaus Schulze-Osthoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernd Dörken
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peter-T Daniel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter-T Daniel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmelz, K., Wieder, T., Tamm, I. et al. Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB. Oncogene 23, 6743–6759 (2004). https://doi.org/10.1038/sj.onc.1207848

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207848

Keywords

This article is cited by

Search

Advanced search

Quick links